Louise Conradsen will become the daily manager of the office in Odense. She is the CEO of the subsidiary CannGros ApS ("CannGros") and sales manager of DanCann Pharma - and lives almost next door to the new office, located at Lille Gråbrødrestræde 1, 5000 Odense C.

"A large part of the Danish cannabis industry is located on Fyn, and we have for a long time been looking for suitable facilities in the local area. We have now found them in the old post office," says Louise Conradsen.

Since its founding in 2018, DanCann Pharma has taken huge steps towards establishing itself as a producer and distributor of products on the market for medical cannabis. When the company acquired the wholesale company CannGros in the fall of 2021, DanCann Pharma became the market leader with license and sales rights for three available products on the market under the Danish Pilot Programme.

"CannGros was the first company to be approved by the Danish Medicines Agency for the import and handling of medical cannabis under the Danish Pilot Programme back in 2018. Recently, we moved the repackaging and distribution activities in CannGros from Glostrup to Ansager in order to have the group's activities consolidated at the headquarters in Southwest Jutland, and the opening of a new location in Odense does not change that. For the time being, there will only be commercial and regulatory activities here," says Louise Conradsen, who also points out that being able to offer a workplace centrally in Denmark may make it easier to attract new colleagues, if that becomes relevant later on.

At the end of 2022, DanCann Pharma received its EU-GMP certification from the Danish Medicines Agency and is therefore looking into a future where the commercial aspect will be more in focus. Both in connection with the sale of own production, but also to a large extent through an upgrading and expansion of the activities in CannGros.

"CannGros has proven to be a really strong acquisition and an important addition to DanCann Pharma. We have connected the desired commercial aspect to our Company, and it has already yielded results with the recently concluded distribution agreements with German WEECO Pharma and Polish Storkpharm, which together have a value of more than DKK 80 million distributed over the next three years," says the CEO of CannGros.

For more information

Louise Conradsen, CEO of CannGros,

Phone: 5384 6353

E-mail: loc@dancann.com

About CannGros

CannGros ApS is approved for the production of cannabis products for medical use, in accordance with the law on the Danish Pilot Programme for medical cannabis. CannGros currently has three products (dried flowers and granules) included on the Danish Medicines Agency's list of medical cannabis products under the Danish Pilot Programme for medical cannabis, with import and distribution of the products Bedrocan®, Bedica®, and Bediol® to all the country's pharmacies.

About DanCann Pharma

DanCann Pharma A/S (SS: DANCAN) (OTCQB: DCPXF) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a licensed production and distribution Company.

The Company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

DanCann Pharma is EU-GMP-approved by the Danish Medicines Agency under the Danish Pilot Programme for medical cannabis, and have, among other things, license for manufacturing, export, import and distribution. The DanCann Pharma group also owns the subsidiary CannGros ApS, which is the market leader in Denmark with the import and distribution of the products Bedrocan®, Bedica® and Bediol® to all the Danish pharmacies.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen/Stockholm and sidelisted on OTCQB Venture Market in USA (OTCQB: DCPXF).

For more information, visit: www.dancann.com

Forward-looking-statement:

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.